Association of Colon Cancer Susceptibility With P53 Gene Codon 72 And Pai-1 Gene 4g/5g Polymorphisms

Yıl 2017, Cilt: 5 Sayı: 2, 431 - 434, 01.12.2017

Banu Bayram , Mete Özkurt Bartu Badak , Nilüfer Erkasap Serdar Erkasap Bülent Yıldız Enver İhtiyar

Öz

We aimed to investigate the relationship between colon cancer and p53 gene codon 72 and PAI-1 gene 4G/5G polymorphism in a Turkish study population. Genomic DNA was extracted from 72 patients with colon cancer and 76 controls. PCR technique was used to amplify extracted DNA with proper primers for each polymorphism. For identifying genotypes PCR products were assessed with UV transilluminator by being exposed to agarose gel electrophoresis. There was no statistical difference between colon cancer patients and controls according to p53 gene codon 72 genotype distribution and allele frequencies (p>0.05). Due to PAI-1 gene 4G/5G genotype distribution 4G4G genotype was frequently higher in colon cancer patients compared to controls  (p<0.05). As a conclusion of our study we may assert that p53 gene codon 72 polymorphism should not be related as a susceptibility factor for colon cancer development in the studied Turkish population while PAI-1 gene 4G/5G polymorphism should be related.

Anahtar Kelimeler

Colon, Cancer, Gene, Polymorphism, PAI-1

Kolon Kanserine Yatkınlık ile p53 Geni Kodon 72 ve PAI-1 Geni 4G/5G Polimorfizmleri Arasındaki İlişki

Öz

Bu çalışmada Türk popülasyonunda kolon kanseri ile p53 geni kodon 72 ve PAI-1 geni 4G/5G polimorfizmleri arasındaki ilişkinin araştırılması amaçlanmıştır. Genomik DNA 72 kolon kanserli hastadan ve 76 kontrol bireyinden izole edilmiştir. Her bir polimorfizm için uygun primerler kullanılarak izolen edilen DNA PCR tekniği kullanılarak amplifiye edilmiştir. PCR ürünleri genotiplerin belirlenmesi için  agaroz jel elektroforezine tabi tutularak  UV translimünatör ile değerlendirilmiştir. p53 geni kodon 72 genotip dağılımı ve allel frekansları incelendiğinde kolon kanserli hastalar ve kontrol bireyleri arasında istatistiksel olarak bir fark belirlenmemiştir (p>0.05). PAI-1 4G/5G genotip dağılımı ve allel frekansları açısından ise 4G4G genotipi kontrol bireylerine göre kolon kanserli hastalarda daha yüksek bulunmuştur (p>0.05). Elde edilen verilere göre çalışmanın yapıldığı Türk popülasyonunda p53 geni kodon 72 polimorfizminin kolon kanseri gelişiminde bir yatkınlık faktörü olamayacağı, PAI-1 4G/5G polimorfizminin ise olabileceği kanısına varılmıştır.

Anahtar Kelimeler

Kolon, Kanser, Polimorfizm, PAI-1, p53

Kaynakça

• 1. Abderrahmane R, Louhibi L, Moghtit FZ, et al: TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: A West Algerian population study. Pathol Oncol Res 21:629-635, 2015.
• 2. Rodrigues NR, Rowan A, Smith MEF, et al: p53 mutations in colorectal cancer. Proc Natl Acad Sci 87:7555-7559, 1990.
• 3. Zienolddiny S, Skaug V: Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer. Lung Cancer 3:1-14, 2012.
• 4. Sugimura H, Tao H, Suzuki M, et al: Genetic susceptibility to lung cancer. Front Biosci 3:1463-1477, 2011.
• 5. Hirschhorn JN, Lohmueller K, Byrne E, et al: A comprehensive review of genetic association studies. Genetics in Medicine 4:45–61, 2002.
• 6. Soussi T, Wiman KG: TP53: an oncogene in disguise. Cell Death Differ 22(8): 1239-1249, 2015.
• 7. Wang S, Cao Q, Wang X, et al: PAI-1 4G/5G polymorphism contributes to cancer susceptibility: Evidence from Meta-Analysis. Plos One 8(2):e56797, 2013.
• 8. Gunes HV, Cosan DT, Ata N et al: Plasminogen activator inhibitor type-1 gene 4G/5G polymorphism is associated with hypertensive patients in the Turkish Population. Genetic Testing and Molecular Biomarkers 14(3): 303-305, 2010.
• 9. Loktionova A, Watson MA, Stebbings WSL, et al: Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Letters 189:189-196, 2003.
• 10. Kilicci C, Bayram B, Ozkurt M, et al: Plasminogen activator inhibitor type-1 gene 4G/5G polymorphism and polycystic ovary syndrome. Genetic Testing and Molecular Biomarkers 15(7-8):565-567, 2011.
• 11. Proestling K, Hebar A, Pruckner N, et al: The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. Plos One 7(10):e47325, 2012.
• 12. Pérez LO, Abba MC, Dulout FN, et al: Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 12(9):1426-1429, 2006.
• 13. Song HR, Kweon SS, Kim HN, et al: p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer 14:242-247, 2011.
• 14. Basiak J, Smolarz B , Kubryn I, et al: Plasminogen activator inhibitor-1 (PAI-1) level and 4G/5G genetic polymorphism in patients with colorectal cancer. Experimental Oncology 22:48-51, 2000.